Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TRVI
SELLTrevi Therapeutics, Inc. · Healthcare · United States · $2.5B · Avg Vol: $50M/d
COMPANY DESCRIPTION
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic neurological conditions, particularly pruritus (itch) associated with liver and kidney diseases. Its lead candidate, Haduvio (nalbuphine ER), is an oral opioid modulator in late-stage development for pruritus in various indications. Trevi operates as a niche player, addressing significant unmet medical needs in underserved patient populations with chronic pruritic conditions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.19 | -0.14 | -0.47 | -0.32 | — | -0.28 | -0.47 | -0.56 | — |
| Shares | 142.0M | 142.0M | 93.6M | 128.3M | -9.6% | 142.0M | — | — | — |
| Debt | 9.2M | 1.3M | 1.0M | 0.8M | -56.5% | 0.7M | — | — | — |
| Equity | 107.5M | 82.5M | 99.6M | 183.2M | 19.5% | — | — | — | — |
| Op CF | -28.2M | -31.7M | -38.3M | -42.1M | — | -45.3M | — | — | — |
| Inv CF | -107.4M | 59.4M | -21.5M | -94.1M | — | — | — | — | — |
| Fin CF | 111.3M | -7.9M | 61.5M | 121.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TRVI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TRVI | Trevi Therapeutics, Inc.(you) | $2.5B | 34 | SELL |
| IOVA | Iovance Biotherapeutics, Inc. | $2.2B | 35 | HOLD |
| AGIO | Agios Pharmaceuticals, Inc. | $2.2B | 32 | SELL |
| NRIX | Nurix Therapeutics, Inc. | $2.4B | 29 | SELL |
| ATAI | AtaiBeckley Inc. | $2.7B | 30 | SELL |
| ADMA | ADMA Biologics, Inc. | $1.9B | 34 | SELL |
| SLS | SELLAS Life Sciences Group, Inc. | $2.2B | 39 | HOLD |
| RAPP | Rapport Therapeutics, Inc. | $1.9B | 31 | SELL |
| MRVI | Maravai LifeSciences Holdings, Inc. | $2.5B | 42 | HOLD |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.6B | 26 | SELL |
Peer medians: ROE -21.0% · P/E 27.9x · Gross margin 50.0%